Therefore, inhibiting or modulating the NR2F6 pathway, an established regulator of both CD8+ T cells and intestinal barrier function [20], appears to be a unique and promising strategy to mitigate brain tissue damage, thus establishing NR2F6 as a potential therapeutic drug target for mitigating disease severity in CM pathology. This evidence concerns the gene CD8A and cutaneous mastocytosis.